Abstract
The World Health Organization (WHO) defines monoclonal B-Cell Lymphocytosis (MBL) as the presence in Peripheral Blood (PB) of monoclonal populations of B-Lymphocytes (BL) of up to 5x109/L, with the phenotype of Chronic Lymphocytic Leukemia (CLL) typical, CLL atypical, or non-CLL, in the absence of B symptoms or clinical manifestations related to chronic B-Cell Lymphoproliferative Disorders (B-CLPD). It is classified as Low Count (LC) (<500 clonal BL/μL) and High Count (HC) (>500 clonal BL/μL) [1]. It has been described in up to 12% of the healthy adult population [1], a proportion that increases in relatives of patients with CLL/Small Lymphocytic Lymphoma (SLL) to around 15% [2]. It is usually a more frequent entity (28.5%) in people with Hepatitis C virus (HCV) [3] infection, and it tends to persist for a long time (90% of cases) with a progression rate of the MBL-HC to clinical manifest B-CLPD between 1-4% per year [1,2]. Currently, it continues to be an entity under study since its possible evolution to CLL or another B-CLPD is clearly unknown [4].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.